115 related articles for article (PubMed ID: 20005102)
21. Design and synthesis of tricyclic cores for kinase inhibition.
Van Epps S; Fiamengo B; Edmunds J; Ericsson A; Frank K; Friedman M; George D; George J; Goedken E; Kotecki B; Martinez G; Merta P; Morytko M; Shekhar S; Skinner B; Stewart K; Voss J; Wallace G; Wang L; Wang L; Wishart N
Bioorg Med Chem Lett; 2013 Feb; 23(3):693-8. PubMed ID: 23265875
[TBL] [Abstract][Full Text] [Related]
22. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
[TBL] [Abstract][Full Text] [Related]
24. Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT.
Parthasarathy S; Henry K; Pei H; Clayton J; Rempala M; Johns D; De Frutos O; Garcia P; Mateos C; Pleite S; Wang Y; Stout S; Condon B; Ashok S; Lu Z; Ehlhardt W; Raub T; Lai M; Geeganage S; Burkholder TP
Bioorg Med Chem Lett; 2018 Jun; 28(10):1887-1891. PubMed ID: 29655979
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
26. In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma.
Chen HH; Namil A; Severns B; Ward J; Kelly C; Drace C; McLaughlin MA; Yacoub S; Li B; Patil R; Sharif N; Hellberg MR; Rusinko A; Pang IH; Combrink KD
Bioorg Med Chem Lett; 2014 Apr; 24(8):1875-9. PubMed ID: 24684843
[TBL] [Abstract][Full Text] [Related]
27. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.
Koch P; Jahns H; Schattel V; Goettert M; Laufer S
J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117
[TBL] [Abstract][Full Text] [Related]
28. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
29. Imidazo[1,2-a]pyridine-based peptidomimetics as inhibitors of Akt.
Kim YB; Kang CW; Ranatunga S; Yang H; Sebti SM; Del Valle JR
Bioorg Med Chem Lett; 2014 Oct; 24(19):4650-4653. PubMed ID: 25205195
[TBL] [Abstract][Full Text] [Related]
30. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
Hartnett JC; Barnett SF; Bilodeau MT; Defeo-Jones D; Hartman GD; Huber HE; Jones RE; Kral AM; Robinson RG; Wu Z
Bioorg Med Chem Lett; 2008 Mar; 18(6):2194-7. PubMed ID: 18294842
[TBL] [Abstract][Full Text] [Related]
31. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
Reader JC; Matthews TP; Klair S; Cheung KM; Scanlon J; Proisy N; Addison G; Ellard J; Piton N; Taylor S; Cherry M; Fisher M; Boxall K; Burns S; Walton MI; Westwood IM; Hayes A; Eve P; Valenti M; de Haven Brandon A; Box G; van Montfort RL; Williams DH; Aherne GW; Raynaud FI; Eccles SA; Garrett MD; Collins I
J Med Chem; 2011 Dec; 54(24):8328-42. PubMed ID: 22111927
[TBL] [Abstract][Full Text] [Related]
32. Discovery of pyrrolopyrimidine inhibitors of Akt.
Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents.
Kassis P; Brzeszcz J; Bénéteau V; Lozach O; Meijer L; Le Guével R; Guillouzo C; Lewiński K; Bourg S; Colliandre L; Routier S; Mérour JY
Eur J Med Chem; 2011 Nov; 46(11):5416-34. PubMed ID: 21944287
[TBL] [Abstract][Full Text] [Related]
34. Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.
Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
Bioorg Med Chem Lett; 2011 Mar; 21(5):1480-3. PubMed ID: 21288717
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines.
Berg S; Bergh M; Hellberg S; Högdin K; Lo-Alfredsson Y; Söderman P; von Berg S; Weigelt T; Ormö M; Xue Y; Tucker J; Neelissen J; Jerning E; Nilsson Y; Bhat R
J Med Chem; 2012 Nov; 55(21):9107-19. PubMed ID: 22489897
[TBL] [Abstract][Full Text] [Related]
36. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
[TBL] [Abstract][Full Text] [Related]
37. Discovery and SAR of spirochromane Akt inhibitors.
Kallan NC; Spencer KL; Blake JF; Xu R; Heizer J; Bencsik JR; Mitchell IS; Gloor SL; Martinson M; Risom T; Gross SD; Morales TH; Wu WI; Vigers GP; Brandhuber BJ; Skelton NJ
Bioorg Med Chem Lett; 2011 Apr; 21(8):2410-4. PubMed ID: 21392984
[TBL] [Abstract][Full Text] [Related]
38. Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors.
Chen T; Sorna V; Choi S; Call L; Bearss J; Carpenter K; Warner SL; Sharma S; Bearss DJ; Vankayalapati H
Bioorg Med Chem Lett; 2017 Dec; 27(24):5473-5480. PubMed ID: 29150397
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
Barlaam B; Cosulich S; Fitzek M; Germain H; Green S; Hanson LL; Harris CS; Hancox U; Hudson K; Lambert-van der Brempt C; Lamorlette M; Magnien F; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
Bioorg Med Chem Lett; 2017 Jul; 27(13):3030-3035. PubMed ID: 28526367
[TBL] [Abstract][Full Text] [Related]
40. 3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.
Shen J; Li X; Zhang Z; Luo J; Long H; Tu Z; Zhou X; Ding K; Lu X
Chem Biol Drug Des; 2016 Nov; 88(5):690-698. PubMed ID: 27264434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
